The assessment of side effects of tyrosine kinase inhibitors (TKI) applied in patients with advanced thyroid cancer (TC) - one centre experience

被引：0
|
作者：
Jolanta Krajewska
Aleksandra Kukulska
Ewa Paliczka-Cieślik
Daria Handkiewicz-Junak
Tomasz Gawlik
Tomasz Olczyk
Aleksandra Kropińska
Aleksander Skoczylas
Barbara Michalik
Barbara Jarząb
机构：
[1] M. Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology,
[2] Gliwice Branch,undefined
来源：
Thyroid Research | / 6卷 / Suppl 2期
关键词：
Meningitis; Thyroid Cancer; Tyrosine Kinase Inhibitor; Lymphopenia; Prospective Clinical Trial;
D O I：
10.1186/1756-6614-6-S2-A33
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Oral dysesthesia in cancer patients (Pts) treated with multitargeted tyrosine kinase inhibitors (MT-TKI).
    Yuan, Anna D.
    Kurtz, Sharyn L.
    Barysauskas, Constance
    Pilotte, Amy P.
    Wagner, Andrew J.
    Treister, Nathaniel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] Effect of Pre-Existent Sarcopenia on Oncological Outcome of Advanced Thyroid Cancer Patients Treated with Tyrosine Kinase Inhibitors
    Dalmiglio, Cristina
    Brilli, Lucia
    Ciuoli, Cristina
    Maino, Fabio
    Valerio, Laura
    Sannino, Ida
    Cartocci, Alessandra
    Guerrini, Susanna
    Zanoni, Matteo
    Marrazzo, Giuseppe
    Mazzei, Maria Antonietta
    Castagna, Maria Grazia
    CANCERS, 2022, 14 (19)
  • [23] Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice
    Molina-Vega, M.
    Garcia-Aleman, J.
    Sebastian-Ochoa, A.
    Mancha-Doblas, I.
    Trigo-Perez, J. M.
    Tinahones-Madueno, F.
    ENDOCRINE, 2018, 59 (02) : 395 - 401
  • [24] Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice
    M. Molina-Vega
    J. García-Alemán
    A. Sebastián-Ochoa
    I. Mancha-Doblas
    J. M. Trigo-Pérez
    F. Tinahones-Madueño
    Endocrine, 2018, 59 : 395 - 401
  • [25] Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors
    Terada, Tomohiro
    Noda, Satoshi
    Inui, Ken-ichi
    PHARMACOLOGY & THERAPEUTICS, 2015, 152 : 125 - 134
  • [26] Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer
    Lin, Chi-Iou
    Whang, Edward E.
    Lorch, Jochen H.
    Ruan, Daniel T.
    SURGERY, 2012, 152 (06) : 1142 - 1149
  • [27] The Effects of Four Different Tyrosine Kinase Inhibitors on Medullary and Papillary Thyroid Cancer Cells
    Verbeek, Hans H. G.
    Alves, Maria M.
    de Groot, Jan-Willem B.
    Osinga, Jan
    Plukker, John T. M.
    Links, Thera P.
    Hofstra, Robert M. W.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (06): : E991 - E995
  • [28] Tyrosine Kinase Inhibitors in the Treatment of Differentiated Thyroid Cancer: Efficacy and Tolerability in 17 Patients
    Santos, Rita Joana
    Vieira, Margarida da Silva
    Marques, Pedro
    Limbert, Edward
    Leite, Valeriano
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [29] How to Incorporate New Tyrosine Kinase Inhibitors in the Treatment of Patients With Medullary Thyroid Cancer
    Haddad, Robert I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) : 3618 - 3620
  • [30] Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials
    Liu, Jen-Wei
    Chen, Chiehfeng
    Loh, El-Wui
    Chu, Chun-Cheng
    Wang, Mu-Yi
    Ouyang, Hsin-Ju
    Chang, Ya-Ting
    Zhuang, Wei-Zhan
    Chou, Ching-Wen
    Huang, Der-Jr
    Lee, Chia-Hwa
    Yen, Yun
    Tam, Ka-Wai
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (05) : 795 - 803
12345